Abstract
Purpose
Autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare complicated primary immunodeficiency disease (PID). Signal transducer and activator of transcription 3 (STAT3) gene mutation is found to cause AD-HIES. The distribution of AD-HIES patients with STAT3 deficiency in the Chinese population is not clear. Herein, we retrospectively report 17 AD-HIES patients with STAT3 deficiency and demonstrate their clinical, immunological, and genetic features.
Methods
Patients’ clinical data were collected from their medical records. Routine laboratory testing results included lymphocyte subset analysis and immunoglobulin quantification. STAT3 mutations were investigated by sequencing of genomic DNA.
Results
Among 575 patients with PID, 28 (4.87%) were clinically diagnosed as HIES. Among them, 17 (2.96%) were confirmed as STAT3 mutant AD-HIES. The ratio of male to female patients was 8:9. All of the 17 patients had NIH scores over 40 points. The mean ages at onset and diagnosis were 1.05 and 10.35 years, respectively. Three patients (17.65%, 3/17) died with a mean age of 13.33 years. Eczema, recurrent skin infection, and respiratory tract infection were the most common clinical symptoms and are present in all of the 17 patients in this study. Six patients (37.5%, 6/16) suffered complication from BCG vaccination. Noninfection symptoms are characteristic facial features in 17 patients (100%, 17/17), retention of primary teeth in 10 patients (90.91%, 10/11), and abnormal bone fractures in 7 patients (41.18%, 7/17). Eleven types of STAT3 mutations were identified in 17 patients, including 1 novel mutation.
Conclusions
We here retrospectively report the largest Chinese cohort of AD-HIES patients with STAT3 mutation. Unique features, when compared to existing literature reports, include (1) later age of diagnosis, (2) significantly higher rate of BCG complications, and (3) lower rate of candidiasis and chronic otitis media.
Similar content being viewed by others
References
Davis SD, Schaller J, Wedgwood RJ. Job’s syndrome. Recurrent, “cold”, staphylococcal abscesses. Lancet. 1966;1(7445):1013–5.
Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972;49(1):59–70.
Rezaei N, Aghamohammadi A. Hyper-IgE syndrome. J Postgrad Med. 2010;56(2):63–4. doi:10.4103/0022-3859.65271.
Minegishi Y, Karasuyama H. Genetic origins of hyper-IgE syndrome. Curr Allergy Asthma Rep. 2008;8(5):386–91.
Wu G, Hitchen PG, Panico M, North SJ, Barbouche MR, Binet D, et al. Glycoproteomic studies of IgE from a novel hyper IgE syndrome linked to PGM3 mutation. Glycoconj J. 2016;33(3):447–56. doi:10.1007/s10719-015-9638-y.
Qin T, An Y, Liu C, Wu J, Dai R, Liu D, et al. Novel DOCK8 gene mutations lead to absence of protein expression in patients with hyper-IgE syndrome. Immunol Res. 2016;64(1):260–71. doi:10.1007/s12026-015-8745-y.
Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608–19. doi:10.1056/NEJMoa073687.
Mogensen TH. STAT3 and the hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. Jak-Stat. 2013;2(2):e23435. doi:10.4161/jkst.23435.
Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250:25–32. doi:10.1111/j.1749-6632.2011.06387.x.
Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol. 2009;21(5):487–92. doi:10.1016/j.coi.2009.07.013.
Ives ML, Ma CS, Palendira U, Chan A, Bustamante J, Boisson-Dupuis S, et al. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function. J Allergy Clin Immunol. 2013;132(2):400–11 e9.
Kane A, Deenick EK, Ma CS, Cook MC, Uzel G, Tangye SG. STAT3 is a central regulator of lymphocyte differentiation and function. Curr Opin Immunol. 2014;28:49–57. doi:10.1016/j.coi.2014.01.015.
Linnekin D, Mou S, Deberry CS, Weiler SR, Keller JR, Ruscetti FW, et al. Stem cell factor, the JAK-STAT pathway and signal transduction. Leuk Lymphoma. 1997;27(5–6):439–44. doi:10.3109/10428199709058310.
Weber-Nordt RM, Mertelsmann R, Finke J. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma. 1998;28(5–6):459–67. doi:10.3109/10428199809058353.
Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551–7. doi:10.1084/jem.20080218.
Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452(7188):773–6. doi:10.1038/nature06764.
Sharma S, Saikia B, Goel S, Rawat A, Minz RW, Suri D, et al. TH17 cells in STAT3 related hyper-IgE syndrome. Indian J Pediatr. 2016. doi:10.1007/s12098-016-2150-y.
Speckmann C, Enders A, Woellner C, Thiel D, Rensing-Ehl A, Schlesier M, et al. Reduced memory B cells in patients with hyper IgE syndrome. Clin Immunol. 2008;129(3):448–54. doi:10.1016/j.clim.2008.08.002.
Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651–62. doi:10.1038/nrm909.
Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–9.
O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–87. doi:10.1016/j.immuni.2008.03.002.
Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125(2):424–32 e8.
Jiao H, Toth B, Erdos M, Fransson I, Rakoczi E, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46(1):202–6. doi:10.1016/j.molimm.2008.07.001.
Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine. 2012;91(4):e1–19. doi:10.1097/MD.0b013e31825f95b9.
Xie L, Hu X, Li Y, Zhang W, Chen L. Hyper-IgE syndrome with STAT3 mutation: a case report in Mainland China. Clin Dev Immunol. 2010;2010:289873.
Zeng H, Tao Y, Chen X, Zeng P, Wang B, Wei R, et al. Primary immunodeficiency in South China: clinical features and a genetic subanalysis of 138 children. J Investig Allergology Clin Immunol. 2013;23(5):302–8.
Liu JY, Li Q, Chen TT, Guo X, Ge J, Yuan LX. Destructive pulmonary staphylococcal infection in a boy with hyper-IgE syndrome: a novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene (p.Y657S). Eur J Pediatr. 2011;170(5):661–6. doi:10.1007/s00431-010-1349-6.
Zhang LY, Tian W, Shu L, Jiang LP, Zhan YZ, Liu W, et al. Clinical features, STAT3 gene mutations and Th17 cell analysis in nine children with hyper-IgE syndrome in mainland China. Scand J Immunol. 2013;78(3):258–65. doi:10.1111/sji.12063.
Li ZT, Wang S, Wang X. Mutation analysis of the STAT3 gene in a patient with hyper-IgE syndrome. Chin J Dermatol. 2015;48:735–7.
Liu JR, Duan XM, Guo AX, Zhao SY, Jiang ZF. A case report of hyper IgE syndrome combined with pulmonary arterial disorders. Chin J Pediatr. 2013;51:692–3.
Xue L, Zhang M, Yang Y, Wang S. Mutation analysis of the STAT3 gene in a patient with hyper-IgE syndrome. Chin J Dermatol. 2013;46:716–8.
Zhang GQ, Cao L, Zhu CM, Wang YJ. STAT3 gene mutation associated with hyper-immunoglobulin E syndrome: a case study and the review of the related literature. Chin J Appl Clin Pediatr. 2016;31:309–11.
Lee WI, Huang JL, Lin SJ, Yeh KW, Chen LC, Ou LS, et al. Clinical, immunological and genetic features in Taiwanese patients with the phenotype of hyper-immunoglobulin E recurrent infection syndromes (HIES). Immunobiology. 2011;216(8):909–17. doi:10.1016/j.imbio.2011.01.008.
Group CTFPs. The French national registry of primary immunodeficiency diseases. Clin Immunol. 2010;135(2):264–72. doi:10.1016/j.clim.2010.02.021.
Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31(6):968–76. doi:10.1007/s10875-011-9594-7.
Lee WI, Huang JL, Jaing TH, Shyur SD, Yang KD, Chien YH, et al. Distribution, clinical features and treatment in Taiwanese patients with symptomatic primary immunodeficiency diseases (PIDs) in a nationwide population-based study during 1985–2010. Immunobiology. 2011;216(12):1286–94. doi:10.1016/j.imbio.2011.06.002.
Ma H, Kuang L, Lv G, Wang B, Lian Z. Vertebral aspergillosis in a patient with autosomal-dominant hyper-IgE syndrome. Clin Vaccine Immunol: CVI. 2014;21(1):107–9. doi:10.1128/CVI.00529-13.
Zhong H, Song Z, Wang H, Zhang W, Hao F. A child case of hyper-IgE syndrome. Allergy. 2010;65(12):1622–3.
Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122(1):181–7. doi:10.1016/j.jaci.2008.04.037.
Jinnestal CL, Belfrage E, Back O, Schmidtchen A, Sonesson A. Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis. Int J Dermatol. 2014;53(1):27–33. doi:10.1111/ijd.12198.
Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144(1):1–9. doi:10.1111/j.1365-2249.2005.02980.x.
Garty BZ, Ben-Baruch A, Rolinsky A, Woellner C, Grimbacher B, Marcus N. Pneumocystis jirovecii pneumonia in a baby with hyper-IgE syndrome. Eur J Pediatr. 2010;169(1):35–7. doi:10.1007/s00431-009-0973-5.
Esposito L, Poletti L, Maspero C, Porro A, Pietrogrande MC, Pavesi P, et al. Hyper-IgE syndrome: dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(2):147–53.
Chandesris MO, Azarine A, Ong KT, et al. Frequent and widespread vascular abnormalities in human STAT3 deficiency. Artery Res. 2011;5(4):163.
Dang Y, Ren J, Guo Y, Geng S. Hyper IgE syndrome. Indian Dermatol Online J. 2014;5(1):69–71.
Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in human disease. J Clin Immunol. 2015;35(7):615–23. doi:10.1007/s10875-015-0187-8.
Acknowledgments
We thank all the blood donors and the nursing staffs in Shanghai Children’s Medical Center for the collection of specimens. We also thank Prof. Wei Zhao in Virginia Commonwealth University School of Medicine and Prof. Ji-Wen Li in East China Normal University for helping us edit the language. This research was supported by grants from the National Natural Science Foundation of China (81273314, 81571605), Shanghai Municipal Education Commission (14ZZ105), and Project HOPE of The Abbott Fund Institute of Nutrition Science (AFINS-HOPE-2013-15).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Jing Wu, Ji Chen, and Zhi-Qing Tian are the co-first authors, and they contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wu, J., Chen, J., Tian, ZQ. et al. Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review. J Clin Immunol 37, 166–179 (2017). https://doi.org/10.1007/s10875-017-0369-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-017-0369-7